Wave Life Sciences WVE Amortization Of Right Of Use Assets
Amortization Of Right Of Use Assets at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept wve:AmortizationOfRightOfUseAssets.
The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Wave Life Sciences's amortization of right of use assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Wave Life Sciences's amortization of right of use assets?
- Wave Life Sciences (WVE) reported amortization of right of use assets of $1.46M in Q1 2026.
- How has Wave Life Sciences's amortization of right of use assets changed year-over-year?
- Wave Life Sciences's amortization of right of use assets increased by 13.6% year-over-year, from $1.29M to $1.46M.
- What is the long-term trend for Wave Life Sciences's amortization of right of use assets?
- Over 4 years (2021 to 2025), Wave Life Sciences's amortization of right of use assets has grown at a 23.2% compound annual growth rate (CAGR), from $2.35M to $5.41M.
- What does amortization of right of use assets mean?
- This represents the non-cash expense recognized over the lease term for the right-of-use asset created under operating lease agreements. It reflects the systematic consumption of the economic benefits derived from leased office or laboratory space. Investors track this to understand the underlying operational cost structure independent of cash lease payments.